Optic Neuritis
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Optic Neuritis

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Optic Neuritis Local Doctors?
Elite in Optic Neuritis
Elite in Optic Neuritis
Referral may be required

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
Languages Spoken:
English

Peter Calabresi is a Neurologist practicing medicine in Baltimore, Maryland. Dr. Calabresi is rated as an Elite provider by MediFind in the treatment of Optic Neuritis. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Optic Neuritis, Relapsing Multiple Sclerosis (RMS), and CACH Syndrome.

Distinguished in Optic Neuritis
Distinguished in Optic Neuritis
Referral may be required

Vanderbilt Medical Group- Teleneurology

1161 21st Ave South, A-0118 Medical Center North, 
Nashville, TN 
Languages Spoken:
English
Offers Telehealth

Francesca Bagnato is a Neurologist practicing medicine in Nashville, Tennessee. Dr. Bagnato is rated as a Distinguished provider by MediFind in the treatment of Optic Neuritis. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Multiple Sclerosis (MS), Neuromyelitis Optica, Optic Neuritis, and Relapsing Multiple Sclerosis (RMS). Dr. Bagnato is board certified in  .

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Optic Neuritis
Elite in Optic Neuritis
Referral may be required

Johns Hopkins Outpatient Center

Baltimore, MD 
Languages Spoken:
English, Greek
Offers Telehealth

Elias Sotirchos, M.D., specializes in the diagnosis, management and treatment of neuroimmunological disorders that involve the central nervous system, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). His research focuses on developing and validating novel imaging and blood-based biomarkers of these conditions, and clinical trials of experimental therapeutic agents. Dr. Sotirchos earned his medical degree from the National and Kapodistrian University of Athens and subsequently completed his internship and neurology residency training at The Johns Hopkins Hospital. He then pursued advanced clinical and research training in neuroimmunology at Johns Hopkins as a National MS Society Sylvia Lawry Fellow. Dr. Sotirchos is rated as an Elite provider by MediFind in the treatment of Optic Neuritis. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Optic Neuritis, Multiple Sclerosis (MS), Neuromyelitis Optica, and Transverse Myelitis. Dr. Sotirchos is board certified in American Board Of Psychiatry And Neurology.

What are the latest Optic Neuritis Clinical Trials?
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Summary: The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Summary: This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.